237 related articles for article (PubMed ID: 30348991)
1. BMI1 is a therapeutic target in recurrent medulloblastoma.
Bakhshinyan D; Venugopal C; Adile AA; Garg N; Manoranjan B; Hallett R; Wang X; Mahendram S; Vora P; Vijayakumar T; Subapanditha M; Singh M; Kameda-Smith MM; Qazi M; McFarlane N; Mann A; Ajani OA; Yarascavitch B; Ramaswamy V; Farooq H; Morrissy S; Cao L; Sydorenko N; Baiazitov R; Du W; Sheedy J; Weetall M; Moon YC; Lee CS; Kwiecien JM; Delaney KH; Doble B; Cho YJ; Mitra S; Kaplan D; Taylor MD; Davis TW; Singh SK
Oncogene; 2019 Mar; 38(10):1702-1716. PubMed ID: 30348991
[TBL] [Abstract][Full Text] [Related]
2. FoxG1 interacts with Bmi1 to regulate self-renewal and tumorigenicity of medulloblastoma stem cells.
Manoranjan B; Wang X; Hallett RM; Venugopal C; Mack SC; McFarlane N; Nolte SM; Scheinemann K; Gunnarsson T; Hassell JA; Taylor MD; Lee C; Triscott J; Foster CM; Dunham C; Hawkins C; Dunn SE; Singh SK
Stem Cells; 2013 Jul; 31(7):1266-77. PubMed ID: 23592496
[TBL] [Abstract][Full Text] [Related]
3. PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma.
Singh AR; Joshi S; Zulcic M; Alcaraz M; Garlich JR; Morales GA; Cho YJ; Bao L; Levy ML; Newbury R; Malicki D; Messer K; Crawford J; Durden DL
PLoS One; 2016; 11(3):e0150836. PubMed ID: 26938241
[TBL] [Abstract][Full Text] [Related]
4. Notch1 regulates the initiation of metastasis and self-renewal of Group 3 medulloblastoma.
Kahn SA; Wang X; Nitta RT; Gholamin S; Theruvath J; Hutter G; Azad TD; Wadi L; Bolin S; Ramaswamy V; Esparza R; Liu KW; Edwards M; Swartling FJ; Sahoo D; Li G; Wechsler-Reya RJ; Reimand J; Cho YJ; Taylor MD; Weissman IL; Mitra SS; Cheshier SH
Nat Commun; 2018 Oct; 9(1):4121. PubMed ID: 30297829
[TBL] [Abstract][Full Text] [Related]
5. Polycomb group gene BMI1 controls invasion of medulloblastoma cells and inhibits BMP-regulated cell adhesion.
Merve A; Dubuc AM; Zhang X; Remke M; Baxter PA; Li XN; Taylor MD; Marino S
Acta Neuropathol Commun; 2014 Jan; 2():10. PubMed ID: 24460684
[TBL] [Abstract][Full Text] [Related]
6. Enhanced inhibition of clonogenic survival of human medulloblastoma cells by multimodal treatment with ionizing irradiation, epigenetic modifiers, and differentiation-inducing drugs.
Patties I; Kortmann RD; Menzel F; Glasow A
J Exp Clin Cancer Res; 2016 Jun; 35(1):94. PubMed ID: 27317342
[TBL] [Abstract][Full Text] [Related]
7. Foretinib is effective therapy for metastatic sonic hedgehog medulloblastoma.
Faria CC; Golbourn BJ; Dubuc AM; Remke M; Diaz RJ; Agnihotri S; Luck A; Sabha N; Olsen S; Wu X; Garzia L; Ramaswamy V; Mack SC; Wang X; Leadley M; Reynaud D; Ermini L; Post M; Northcott PA; Pfister SM; Croul SE; Kool M; Korshunov A; Smith CA; Taylor MD; Rutka JT
Cancer Res; 2015 Jan; 75(1):134-46. PubMed ID: 25391241
[TBL] [Abstract][Full Text] [Related]
8. Combination of BMI1 and MAPK/ERK inhibitors is effective in medulloblastoma.
Badodi S; Pomella N; Lim YM; Brandner S; Morrison G; Pollard SM; Zhang X; Zabet NR; Marino S
Neuro Oncol; 2022 Aug; 24(8):1273-1285. PubMed ID: 35213723
[TBL] [Abstract][Full Text] [Related]
9. HDAC and MAPK/ERK Inhibitors Cooperate To Reduce Viability and Stemness in Medulloblastoma.
da Cunha Jaeger M; Ghisleni EC; Cardoso PS; Siniglaglia M; Falcon T; Brunetto AT; Brunetto AL; de Farias CB; Taylor MD; Nör C; Ramaswamy V; Roesler R
J Mol Neurosci; 2020 Jun; 70(6):981-992. PubMed ID: 32056089
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of WNT signaling attenuates self-renewal of SHH-subgroup medulloblastoma.
Rodriguez-Blanco J; Pednekar L; Penas C; Li B; Martin V; Long J; Lee E; Weiss WA; Rodriguez C; Mehrdad N; Nguyen DM; Ayad NG; Rai P; Capobianco AJ; Robbins DJ
Oncogene; 2017 Nov; 36(45):6306-6314. PubMed ID: 28714964
[TBL] [Abstract][Full Text] [Related]
11. Developmental phosphoproteomics identifies the kinase CK2 as a driver of Hedgehog signaling and a therapeutic target in medulloblastoma.
Purzner T; Purzner J; Buckstaff T; Cozza G; Gholamin S; Rusert JM; Hartl TA; Sanders J; Conley N; Ge X; Langan M; Ramaswamy V; Ellis L; Litzenburger U; Bolin S; Theruvath J; Nitta R; Qi L; Li XN; Li G; Taylor MD; Wechsler-Reya RJ; Pinna LA; Cho YJ; Fuller MT; Elias JE; Scott MP
Sci Signal; 2018 Sep; 11(547):. PubMed ID: 30206138
[TBL] [Abstract][Full Text] [Related]
12. Medulloblastoma: Molecular understanding, treatment evolution, and new developments.
Liu X; Ding C; Tan W; Zhang A
Pharmacol Ther; 2020 Jun; 210():107516. PubMed ID: 32105673
[TBL] [Abstract][Full Text] [Related]
13. An autocrine ActivinB mechanism drives TGFβ/Activin signaling in Group 3 medulloblastoma.
Morabito M; Larcher M; Cavalli FM; Foray C; Forget A; Mirabal-Ortega L; Andrianteranagna M; Druillennec S; Garancher A; Masliah-Planchon J; Leboucher S; Debalkew A; Raso A; Delattre O; Puget S; Doz F; Taylor MD; Ayrault O; Bourdeaut F; Eychène A; Pouponnot C
EMBO Mol Med; 2019 Aug; 11(8):e9830. PubMed ID: 31328883
[TBL] [Abstract][Full Text] [Related]
14. Survivin as a therapeutic target in Sonic hedgehog-driven medulloblastoma.
Brun SN; Markant SL; Esparza LA; Garcia G; Terry D; Huang JM; Pavlyukov MS; Li XN; Grant GA; Crawford JR; Levy ML; Conway EM; Smith LH; Nakano I; Berezov A; Greene MI; Wang Q; Wechsler-Reya RJ
Oncogene; 2015 Jul; 34(29):3770-9. PubMed ID: 25241898
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of Bmi1 in breast cancer stem cells suppresses tumor growth and proliferation.
Srinivasan M; Bharali DJ; Sudha T; Khedr M; Guest I; Sell S; Glinsky GV; Mousa SA
Oncotarget; 2017 Jun; 8(24):38731-38742. PubMed ID: 28418883
[TBL] [Abstract][Full Text] [Related]
16. Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma.
Han Y; Lindner S; Bei Y; Garcia HD; Timme N; Althoff K; Odersky A; Schramm A; Lissat A; Künkele A; Deubzer HE; Eggert A; Schulte JH; Henssen AG
Cancer Lett; 2019 Mar; 445():24-33. PubMed ID: 30611741
[TBL] [Abstract][Full Text] [Related]
17. Medulloblastoma cancer stem cells: molecular signatures and therapeutic targets.
Bahmad HF; Poppiti RJ
J Clin Pathol; 2020 May; 73(5):243-249. PubMed ID: 32034059
[TBL] [Abstract][Full Text] [Related]
18. Molecular and in vivo characterization of cancer-propagating cells derived from MYCN-dependent medulloblastoma.
Ahmad Z; Jasnos L; Gil V; Howell L; Hallsworth A; Petrie K; Sawado T; Chesler L
PLoS One; 2015; 10(3):e0119834. PubMed ID: 25785590
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of HMGA1 deregulates tumor growth via cdc25A and alters migration/invasion through a cdc25A-independent pathway in medulloblastoma.
Lau KM; Chan QK; Pang JC; Ma FM; Li KK; Yeung WW; Cheng AS; Feng H; Chung NY; Li HM; Zhou L; Wang Y; Mao Y; Ng HK
Acta Neuropathol; 2012 Apr; 123(4):553-71. PubMed ID: 22249617
[TBL] [Abstract][Full Text] [Related]
20. Medulloblastoma stem cells: modeling tumor heterogeneity.
Manoranjan B; Venugopal C; McFarlane N; Doble BW; Dunn SE; Scheinemann K; Singh SK
Cancer Lett; 2013 Sep; 338(1):23-31. PubMed ID: 22796365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
